Pravastatin
Pravastatin. Hydrophilic — low hepatocellular + CNS penetration → fewer interactions + fewer CNS side effects. Minimal CYP metabolism (sulfation… Oral half-life 1.8 h.
Hydrophilic — low hepatocellular + CNS penetration → fewer interactions + fewer CNS side effects. Minimal CYP metabolism (sulfation pathway). Good choice for patients on complex interaction profiles.
PK: a pure attribution failure — all three values are real and none of them is in the cited paper, which studied heart-transplant recipients ON CYCLOSPORIN, a transporter interaction that raises pravastatin exposure about twelve-fold, and is a drug-interaction study rather than a baseline one. Re-pointed to Singhvi 1990 (PMID:2106337), eight healthy men in a crossover WITH A REAL INTRAVENOUS ARM: verbatim "the oral bioavailability was about 18%" (the stored 0.17 was a rounding down), "0.8 and 1.8 h for the intravenous and oral routes" and "the steady-state volume of distribution averaged 0.51 kg-1", which is 35.7 L at 70 kg. That volume is measured after intravenous dosing, so it is a TRUE Vss and pairs legitimately with the bioavailability — this is the one record in the batch where that pairing is clean. ka 1.5 /h dropped as a Tmax collision.
Pharmacokinetics
- Oral — t½ 1.8 h · F 18% · Vd 35.7 L
Sources: PMID:11192473, PMID:2106337